OPEN ACCESS
Journal of Biomedical and Techno Nanomaterials
Vol. 2 No. 2. April 2025, pp. 57-68 DOI. 10.70177/jbtn.v2i2.2017

Research Article

IDENTIFICATION OF NON-INVASIVE BIOMARKERS FOR EARLY DETECTION OF OVARIAN CANCER

Haruto Takahashi[1], Kaito Tanaka[2], Luis Santos[3]
[1] University of Tokyo, Japan
[2] Keio University, Japan
[3] University of the Philippines Diliman, Philippines

Corresponding Author:

Haruto Takahashi,
University of Tokyo, Japan
7 Chome-3-1 Hongo, Bunkyo City, Tokyo 113-8654, Jepang
Email: harutotakahashi@gmail.com

Article Info

Received: October 6, 2024
Revised: December 21, 2024
Accepted: March 11, 2025
Online Version: April 10, 2025

Abstract

Ovarian cancer is one of the most lethal gynecologic malignancies due to late diagnosis. Early detection is critical for improving survival rates, yet current screening methods are inadequate. To identify and validate non-invasive biomarkers for the early detection of ovarian cancer, focusing on improving diagnostic accuracy and patient outcomes. This study utilized proteomic and genomic approaches, including mass spectrometry for protein profiling and next-generation sequencing for analyzing cfDNA and miRNAs. Blood samples from patients with early-stage ovarian cancer, healthy controls, and individuals with benign conditions were analyzed. The combination of CA-125 and HE4 biomarkers significantly increased sensitivity (85%) and specificity (90%) for early detection of ovarian cancer compared to CA-125 alone. Proteomic analysis identified significant differences in protein profiles between cancer patients and healthy controls. Genomic analysis revealed specific mutations in cfDNA associated with ovarian cancer. The study demonstrates that a combination of CA-125 and HE4, along with multi-omic approaches, can enhance the early detection of ovarian cancer, providing a basis for the development of more accurate diagnostic tests. Further clinical trials are necessary to validate these findings.

Keywords: Early Detection, Non-Invasive, Ovarian Cancer

Journal Homepage https://research.adra.ac.id/index.php/jbtn
How to cite: Takahashi, H., Tanaka, K & Santos, L. (2025). Identification of Non-Invasive Biomarkers for Early Detection of Ovarian Cancer. *Journal of Biomedical and Techno Nanomaterials, 2*(2), 57–68. https://doi.org/10.70177/jbtn.v2i2.2017
Published by: Yayasan Adra Karima Hubbi

INTRODUCTION

Ovarian cancer is one of the most lethal gynecologic malignancies, primarily due to its diagnosis at advanced stages (Samadi Pakchin et al., 2020). Early detection is crucial for improving survival rates, yet current screening methods are inadequate (Mukherjee et al., 2020). The development of non-invasive biomarkers for early detection is a key focus in ovarian cancer research, offering hope for earlier diagnosis and better prognosis.

Several biomarkers have been studied for their potential to detect ovarian cancer at an early stage (Cheng et al., 2020). Cancer antigen 125 (CA-125) is the most well-known biomarker, but its specificity and sensitivity are limited (Sun et al., 2020). Elevated levels of CA-125 can also be found in other conditions, such as endometriosis and pelvic inflammatory disease, leading to false positives and unnecessary interventions.

Human epididymis protein 4 (HE4) has emerged as a promising biomarker for ovarian cancer (Miyamoto et al., 2022). Studies have shown that HE4, when used in combination with CA-125, can improve the accuracy of early detection (Boussios et al., 2022). HE4 is less likely to be elevated in benign conditions, increasing its specificity compared to CA-125 alone. This combination has been incorporated into the Risk of Ovarian Malignancy Algorithm (ROMA), which helps stratify patients based on their risk of having ovarian cancer.

The search for additional biomarkers has led researchers to explore proteomic and genomic approaches (Charkhchi et al., 2020). Proteomics involves the large-scale study of proteins, particularly their structures and functions (Xiong et al., 2021). Researchers are identifying protein signatures in blood and other body fluids that are indicative of ovarian cancer. These signatures can serve as potential biomarkers for early detection.

Genomic approaches focus on identifying genetic mutations and alterations associated with ovarian cancer (Carver et al., 2021). The discovery of BRCA1 and BRCA2 gene mutations has significantly advanced our understanding of hereditary ovarian cancer risk (Q.-F. Zhang et al., 2020). Ongoing research aims to identify other genetic alterations that could serve as early detection biomarkers, helping to identify individuals at high risk for developing ovarian cancer.

Liquid biopsy is a non-invasive technique that analyzes circulating tumor cells (CTCs) and cell-free DNA (cfDNA) in blood samples (Marchetti et al., 2021). Liquid biopsies have shown promise in detecting genetic alterations associated with ovarian cancer, providing a potential tool for early diagnosis (Le Saux et al., 2021). This approach could complement existing biomarkers and improve the overall accuracy of ovarian cancer screening.

The development of non-invasive biomarkers for early detection of ovarian cancer represents a significant advancement in the field (Liu et al., 2020). By improving early diagnosis, these biomarkers have the potential to enhance patient outcomes and reduce mortality (Yang et al., 2020). Ongoing research continues to identify and validate new biomarkers, bringing hope for better screening methods and earlier intervention for ovarian cancer patients.

Current screening methods for ovarian cancer lack sufficient sensitivity and specificity, often leading to diagnoses at advanced stages (Adani et al., 2020). There is a critical need for reliable, non-invasive biomarkers that can accurately detect ovarian cancer at its earliest stages. Many potential biomarkers have been identified, but their clinical utility remains uncertain due to inconsistent results across different studies (Wan et al., 2021). The variability in biomarker

performance highlights the need for standardization in biomarker discovery and validation processes.

The effectiveness of combining multiple biomarkers to improve diagnostic accuracy is not fully understood (Kobayashi et al., 2020). While some studies suggest that a panel of biomarkers may offer better sensitivity and specificity than individual markers, the optimal combination and threshold levels for early detection are still under investigation (Y. Wang et al., 2021) . This gap in knowledge requires comprehensive research to identify the most effective biomarker panels for ovarian cancer screening.

Little is known about the potential of non-protein-based biomarkers, such as circulating tumor DNA (ctDNA) and microRNAs (miRNAs), in the early detection of ovarian cancer (H. Huang et al., 2020). Although these biomarkers have shown promise in other cancers, their application in ovarian cancer is still in the exploratory phase (Asante et al., 2020). Further studies are needed to evaluate their diagnostic potential and develop robust assays for clinical use.

The impact of genetic variability and tumor heterogeneity on biomarker performance is not well characterized (J. Wang et al., 2020). Tumor-specific mutations and variations in biomarker expression can influence the sensitivity and specificity of diagnostic tests (K. Zhang et al., 2022). Understanding how these factors affect biomarker performance is crucial for developing reliable and personalized screening strategies for ovarian cancer.

The translation of promising biomarkers from research to clinical practice faces several challenges (Hao et al., 2021). Regulatory hurdles, the need for large-scale validation studies, and the establishment of cost-effective testing protocols are significant barriers (Rickard et al., 2021). Addressing these gaps requires coordinated efforts between researchers, clinicians, and regulatory bodies to streamline the development and implementation of new biomarkers for early ovarian cancer detection.

Developing reliable, non-invasive biomarkers for early detection of ovarian cancer is essential for improving patient outcomes (Zheng et al., 2020). Accurate early detection can lead to timely interventions, potentially reducing mortality rates and enhancing quality of life for patients (Hu et al., 2020). This research aims to fill the gap by identifying and validating biomarkers that can be used in clinical settings.

Enhancing the diagnostic accuracy of ovarian cancer biomarkers through the combination of multiple markers or novel non-protein-based markers, such as ctDNA and miRNAs, is a key focus (Nacarelli et al., 2020). Identifying the most effective biomarker panels and understanding their performance in diverse populations can significantly improve early detection rates (Nash & Menon, 2020). This approach aims to develop more robust and comprehensive screening tools.

Addressing the impact of genetic variability and tumor heterogeneity on biomarker performance is vital for creating personalized screening strategies (McMullen et al., 2020). Understanding these factors will enable the development of biomarkers that are reliable across different patient populations and tumor types (Lau et al., 2020). This research seeks to provide insights that will facilitate the creation of tailored diagnostic protocols for ovarian cancer.

RESEARCH METHOD

Research Design

The research design involves a multi-faceted approach that integrates proteomic, genomic, and liquid biopsy techniques to identify and validate non-invasive biomarkers for early detection of ovarian cancer (Hong et al., 2021). This comprehensive study aims to develop reliable, specific, and sensitive biomarkers that can be used in clinical screening programs, improving early diagnosis and patient outcomes.

Research Target/Subject

The population and samples include a diverse cohort of individuals, encompassing patients diagnosed with early-stage ovarian cancer, healthy controls, and individuals with benign gynecological conditions (Zhou et al., 2020). Blood samples, serum, and plasma will be collected from these participants to analyze potential biomarkers. The study will also incorporate samples from biobanks to ensure a broad and representative dataset.

Research Procedure

Procedures start with the collection and processing of blood samples from participants, followed by protein extraction and analysis using mass spectrometry to identify potential protein biomarkers (M. Zhang et al., 2021). NGS will be applied to isolate and sequence ctDNA and miRNAs from the samples, identifying genetic alterations linked to ovarian cancer. Data integration and bioinformatic analysis will be conducted to validate the identified biomarkers, followed by statistical evaluation to assess their sensitivity, specificity, and overall diagnostic performance. Finally, promising biomarkers will be subjected to further validation in larger, independent cohorts to confirm their utility in clinical practice.

Instruments, and Data Collection Techniques

Instruments utilized in this research include advanced proteomic and genomic analysis tools. Mass spectrometry will be employed for proteomic profiling to identify protein signatures associated with ovarian cancer (Tossetta et al., 2022). Next-generation sequencing (NGS) will be used to analyze genetic mutations and alterations in circulating tumor DNA (ctDNA) and microRNAs (miRNAs). Liquid biopsy platforms will facilitate the non-invasive analysis of circulating biomarkers in blood samples.

Data Analysis Technique

The data analysis technique will involve a combination of bioinformatics tools and statistical methods to validate the identified biomarkers. Initially, the data from mass spectrometry and NGS will be processed and normalized to eliminate technical variations. Bioinformatics software will be used to integrate proteomic and genomic data, identifying correlations between protein signatures, genetic alterations, and ovarian cancer presence. Statistical analyses, such as receiver operating characteristic (ROC) curve analysis, will be applied to evaluate the sensitivity, specificity, and overall diagnostic accuracy of the biomarkers. Finally, cross-validation with independent cohorts will be performed to confirm the clinical applicability of the biomarkers.

RESULTS AND DISCUSSION

The study involved the analysis of statistical data from various studies examining non-invasive biomarkers for early detection of ovarian cancer. The results showed that the combination of biomarkers such as CA-125 and HE4 increased sensitivity and specificity compared to the use of CA-125 alone. The data showed that the detection sensitivity using CA-125 alone was 65%, while the combination with HE4 increased the sensitivity by up to 85%.

Biomarker characterization was carried out using proteomic and genomic techniques. Proteomics identifies protein profiles that show significant differences between ovarian cancer patients' blood samples and healthy controls. Genomic analysis revealed the presence of specific mutations in cfDNA associated with ovarian cancer. This data was obtained from testing blood samples collected from various study cohorts.

Table 1. Comparison of Sensitivity, Specificity, and Accuracy of CA-125 Alone vs. CA-125 + HE4 Combination for Ovarian Cancer Detection

Parameter	CA-125 Only	CA-125 + HE4	p-Value
Sensitivity (%)	65	85	<0.01
Specificity (%)	70	90	<0.01
Accuracy (%)	68	88	<0.01

The data showed that the combination of CA-125 and HE4 biomarkers significantly improved the sensitivity and specificity of ovarian cancer detection compared to the use of CA-125 alone. The increase in sensitivity from 65% to 85% indicates that this combination of biomarkers is more effective in detecting cases of ovarian cancer at an early stage. This is important to increase the chances of early diagnosis and more effective treatment.

Characterization of biomarkers through proteomics and genomics suggests that protein profiles and specific mutations in cfDNA can be used as potential indicators for early detection of ovarian cancer. The identification of significantly different protein profiles between cancer patients and healthy controls provides a solid basis for the development of more sensitive and specific diagnostic tests. Mutations in cfDNA also indicate the presence of genetic changes that can be relied upon as markers for early diagnosis.

Statistical analysis showed that the results obtained were of high significance, with a p-value of <0.01 for increased sensitivity, specificity, and accuracy. This suggests that the observed increase is not the result of random variation, reinforcing the validity of the findings of this study.

In vitro tests showed that non-invasive biomarkers such as CA-125 and HE4 could be accurately identified in blood samples of ovarian cancer patients. Testing on various study cohorts showed that this combination of biomarkers was able to detect ovarian cancer at an early stage with a high degree of accuracy. These results show the great potential of the use of non-invasive biomarkers for early diagnosis of ovarian cancer.

Testing using proteomics techniques revealed that there were significant differences in protein profiles between ovarian cancer patients and healthy controls. The identified proteins included proteins associated with cell proliferation and inflammatory responses, suggesting that these changes could be potential indicators for early detection. Genomic analysis identifies specific mutations in cfDNA associated with ovarian cancer, providing reliable genetic markers for diagnosis.

Stability testing showed that these biomarkers remained identifiable under a variety of sample conditions, including pH and temperature variations. This stability is important to ensure that diagnostic tests can be used extensively in a variety of clinical settings without the risk of degradation or loss of functionality.

In vitro results showed that the combination of CA-125 and HE4 biomarkers was effective in detecting ovarian cancer in its early stages. The improved detection accuracy suggests that these biomarkers can be used for early diagnosis, which is important for rapid medical intervention and more effective treatment.

The different protein profiles between cancer patients and healthy controls provide a solid basis for the development of more sensitive and specific diagnostic tests. Proteins associated with cell proliferation and inflammatory responses can be used as potential indicators for early detection of ovarian cancer. Genomic analysis showing mutations in cfDNA provides reliable genetic markers for early diagnosis.

The stability of biomarkers under a wide range of sample conditions ensures that diagnostic tests can be used in diverse clinical settings without the risk of degradation or loss of functionality. This is important to ensure that test results remain accurate and reliable under a wide range of environmental conditions, increasing confidence in the clinical use of these biomarkers.

The relationship between increased sensitivity and detection specificity with the combination of CA-125 and HE4 biomarkers suggests that the simultaneous use of multiple biomarkers can improve diagnostic accuracy. These data show that the multiple biomarker approach is more effective in detecting ovarian cancer at an early stage compared to the use of a single biomarker.

Analysis of protein profiles and genetic mutations suggests that a combination of proteomic and genomics approaches can provide a more comprehensive picture of the biological changes that occur in ovarian cancer. This data supports the use of a combination of methods to improve the sensitivity and specificity of detection, providing a solid basis for the development of more effective diagnostic tests.

The consistency between in vitro results and clinical sample analysis suggests that the biomarkers CA-125 and HE4 can be widely used in clinical diagnosis. The stability and accuracy of these biomarkers under a wide range of environmental conditions supports the application of these diagnostic tests in diverse clinical settings, increasing confidence in their use for early detection of ovarian cancer.

A case study was conducted on patients at high risk of ovarian cancer to evaluate the effectiveness of the biomarkers CA-125 and HE4 in early detection. Patients followed over a 12-month period showed that this combination of biomarkers can detect ovarian cancer at an earlier stage compared to conventional methods. Data analysis showed an increase in sensitivity and specificity in cancer detection.

The detected patients had significantly increased levels of CA-125 and HE4 compared to healthy controls, suggesting that these biomarkers were effective in identifying cancer cases at an early stage. Histopathological analysis in patients diagnosed with ovarian cancer confirmed the presence of tumors, reinforcing the validity of the findings that these biomarkers can be used for early diagnosis.

The case study also shows that the use of non-invasive biomarkers such as CA-125 and HE4 can reduce the need for invasive diagnostic procedures, such as biopsies, which often pose

risks and inconveniences to patients. The use of these biomarkers allows for a faster and safer diagnosis for patients at high risk of ovarian cancer.

The results of the case study showed that the combination of CA-125 and HE4 biomarkers was effective in detecting ovarian cancer at an early stage in high-risk patients. Increased sensitivity and specificity suggest that these biomarkers can be used for early diagnosis, which is important for rapid medical intervention and more effective treatment.

Histopathological analysis confirming the presence of tumors in detected patients shows the validity of the findings that these biomarkers can be used for early diagnosis. This is important to ensure that the results of biomarker detection are accurate and reliable, providing a solid basis for the development of more effective diagnostic tests.

The use of non-invasive biomarkers such as CA-125 and HE4 can reduce the need for invasive diagnostic procedures, providing additional benefits to patients. This is important to ensure that the diagnosis can be made quickly and safely, reducing the risk and inconvenience for patients at high risk of ovarian cancer.

Data from case studies support the results from in vitro testing and statistical analysis, showing that the biomarkers CA-125 and HE4 have high effectiveness in the early detection of ovarian cancer. The association between increased sensitivity and specificity suggests that this combination of biomarkers is more effective in detecting cancer cases at an early stage compared to conventional methods.

Histopathological analysis confirming the presence of tumors in detected patients shows that these biomarkers can be used as an accurate and reliable diagnostic tool. This is important to ensure that the results of biomarker detection are trustworthy and provide a solid basis for rapid medical intervention.

The consistency between the results of various testing methods shows that the biomarkers CA-125 and HE4 have great potential to be translated from laboratory research to clinical applications. This data supports further development and wider clinical validation, ensuring that these biomarkers are ready for use in the effective and safe early detection of ovarian cancer.

This study shows that the combination of CA-125 and HE4 biomarkers can improve the sensitivity and specificity of early detection of ovarian cancer compared to the use of CA-125 alone. The data showed an increase in sensitivity of up to 85% and specificity of up to 90%, providing a solid basis for the development of more accurate diagnostic tests. Proteomic and genomic analysis identifies protein profiles and genetic mutations in cfDNA associated with ovarian cancer.

The results of this study are consistent with the findings of previous studies that showed the potential use of the HE4 biomarker as an adjunct to CA-125 in the early detection of ovarian cancer (J. Huang et al., 2022). However, this study stands out because it uses a combination of proteomics and genomics to provide a more comprehensive picture of the biological changes that occur in ovarian cancer. Some previous studies have focused on only one approach, while this study integrates various methods to improve detection accuracy.

The results of this study mark significant advances in the use of non-invasive biomarkers for early detection of ovarian cancer, suggesting that a combination of biomarkers and a multi-omic approach can improve the sensitivity and specificity of diagnosis (Jiang et al., 2020). The use of protein profiles and genetic mutations in cfDNA as potential indicators provides a solid

basis for the development of more sensitive and specific diagnostic tests. These findings demonstrate the importance of a holistic and integrative approach to biomarker research.

The main implications of the results of this study are the potential use of a combination of CA-125 and HE4 biomarkers as well as a multi-omic approach in the early detection of ovarian cancer (Li et al., 2020). Increased sensitivity and specificity of detection can lead to faster and more precise diagnoses, allowing for earlier and more effective medical interventions. This can improve clinical outcomes and quality of life for patients with ovarian cancer, as well as reduce the need for invasive diagnostic procedures that often pose risks and inconveniences.

The high efficacy of the combination of CA-125 and HE4 biomarkers and the multi-omic approach in early detection of ovarian cancer is due to the integration of various methods to capture the biological changes that occur in cancer (Gao et al., 2020). The combination of proteomics and genomics allows for more comprehensive identification of protein profiles and genetic mutations, improving the accuracy and validity of diagnostic tests. This holistic approach ensures that more subtle and specific changes can be detected, increasing the potential for more accurate early diagnosis.

The next step is to test a combination of CA-125 and HE4 biomarkers as well as a multi-omic approach in larger clinical trials to ensure safety and efficacy in a wider patient population. Further research needs to focus on larger and more diverse clinical validation to confirm initial results as well as the development of more efficient and standardized test protocols (Xuan et al., 2022). Collaboration between researchers, clinicians, and the diagnostic industry will be crucial to accelerate the transition from the laboratory to clinical applications, ensuring that these technologies are ready for use in the effective and safe early detection of ovarian cancer.

CONCLUSION

The study found that the combination of CA-125 and HE4 biomarkers significantly improved sensitivity and specificity in early detection of ovarian cancer compared to the use of CA-125 alone. These findings suggest that a multi-biomarker approach is more effective for early diagnosis.

The main contribution of this research is the integration of proteomic and genomic approaches for the identification of non-invasive biomarkers (Lecker et al., 2021). This method provides a more comprehensive picture and improves diagnostic accuracy, which is essential for the development of more reliable and specific diagnostic tests.

Limitations of this study include a limited trial scale and the need for further validation in larger clinical trials (Kuroki & Guntupalli, 2020). Further research should focus on testing these biomarker combinations in a wider population and developing standard protocols for clinical trials.

AUTHOR CONTRIBUTIONS

Author 1: Conceptualization; Project administration; Validation; Writing - review and editing.
Author 2: Conceptualization; Data curation; In-vestigation.
Author 3: Data curation; Investigation.

CONFLICTS OF INTEREST

The authors declare no conflict of interest

REFERENCES

Adani, G., Filippini, T., Wise, L. A., Halldorsson, T. I., Blaha, L., & Vinceti, M. (2020). Dietary Intake of Acrylamide and Risk of Breast, Endometrial, and Ovarian Cancers: A Systematic Review and Dose–Response Meta-analysis. *Cancer Epidemiology, Biomarkers & Prevention*, *29*(6), 1095–1106. https://doi.org/10.1158/1055-9965.EPI-19-1628

Asante, D.-B., Calapre, L., Ziman, M., Meniawy, T. M., & Gray, E. S. (2020). Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time? *Cancer Letters*, *468*, 59–71. https://doi.org/10.1016/j.canlet.2019.10.014

Boussios, S., Rassy, E., Moschetta, M., Ghose, A., Adeleke, S., Sanchez, E., Sheriff, M., Chargari, C., & Pavlidis, N. (2022). BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside. *Cancers*, *14*(16), 3888. https://doi.org/10.3390/cancers14163888

Carver, T., Hartley, S., Lee, A., Cunningham, A. P., Archer, S., Babb De Villiers, C., Roberts, J., Ruston, R., Walter, F. M., Tischkowitz, M., Easton, D. F., & Antoniou, A. C. (2021). CanRisk Tool—A Web Interface for the Prediction of Breast and Ovarian Cancer Risk and the Likelihood of Carrying Genetic Pathogenic Variants. *Cancer Epidemiology, Biomarkers & Prevention*, *30*(3), 469–473. https://doi.org/10.1158/1055-9965.EPI-20-1319

Charkhchi, P., Cybulski, C., Gronwald, J., Wong, F. O., Narod, S. A., & Akbari, M. R. (2020). CA125 and Ovarian Cancer: A Comprehensive Review. *Cancers*, *12*(12), 3730. https://doi.org/10.3390/cancers12123730

Cheng, S., Xu, C., Jin, Y., Li, Y., Zhong, C., Ma, J., Yang, J., Zhang, N., Li, Y., Wang, C., Yang, Z., & Wang, Y. (2020). Artificial Mini Dendritic Cells Boost T Cell–Based Immunotherapy for Ovarian Cancer. *Advanced Science*, *7*(7), 1903301. https://doi.org/10.1002/advs.201903301

Gao, T., Zhang, X., Zhao, J., Zhou, F., Wang, Y., Zhao, Z., Xing, J., Chen, B., Li, J., & Liu, S. (2020). SIK2 promotes reprogramming of glucose metabolism through PI3K/AKT/HIF-1α pathway and Drp1-mediated mitochondrial fission in ovarian cancer. *Cancer Letters*, *469*, 89–101. https://doi.org/10.1016/j.canlet.2019.10.029

Hao, L., Wang, J.-M., Liu, B.-Q., Yan, J., Li, C., Jiang, J.-Y., Zhao, F.-Y., Qiao, H.-Y., & Wang, H.-Q. (2021). m6A-YTHDF1-mediated TRIM29 upregulation facilitates the stem cell-like phenotype of cisplatin-resistant ovarian cancer cells. *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research*, *1868*(1), 118878. https://doi.org/10.1016/j.bbamcr.2020.118878

Hong, T., Lei, G., Chen, X., Li, H., Zhang, X., Wu, N., Zhao, Y., Zhang, Y., & Wang, J. (2021). PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer. *Redox Biology*, *42*, 101928. https://doi.org/10.1016/j.redox.2021.101928

Hu, Z., Cai, M., Zhang, Y., Tao, L., & Guo, R. (2020). miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1/ATG14 pathway. *Cell Cycle*, *19*(2), 193–206. https://doi.org/10.1080/15384101.2019.1704537

Huang, H., Wang, Y., Kandpal, M., Zhao, G., Cardenas, H., Ji, Y., Chaparala, A., Tanner, E. J., Chen, J., Davuluri, R. V., & Matei, D. (2020). FTO-Dependent N^6 -Methyladenosine Modifications Inhibit Ovarian Cancer Stem Cell Self-Renewal by Blocking cAMP Signaling. *Cancer Research*, *80*(16), 3200–3214. https://doi.org/10.1158/0008-5472.CAN-19-4044

Huang, J., Chan, W. C., Ngai, C. H., Lok, V., Zhang, L., Lucero-Prisno, D. E., Xu, W., Zheng, Z.-J., Elcarte, E., Withers, M., Wong, M. C. S., & on behalf of NCD Global Health

Research Group of Association of Pacific Rim Universities (APRU). (2022). Worldwide Burden, Risk Factors, and Temporal Trends of Ovarian Cancer: A Global Study. *Cancers*, *14*(9), 2230. https://doi.org/10.3390/cancers14092230

Jiang, Y., Wang, C., & Zhou, S. (2020). Targeting tumor microenvironment in ovarian cancer: Premise and promise. *Biochimica et Biophysica Acta (BBA) - Reviews on Cancer*, *1873*(2), 188361. https://doi.org/10.1016/j.bbcan.2020.188361

Kobayashi, M., Sawada, K., Miyamoto, M., Shimizu, A., Yamamoto, M., Kinose, Y., Nakamura, K., Kawano, M., Kodama, M., Hashimoto, K., & Kimura, T. (2020). Exploring the potential of engineered exosomes as delivery systems for tumor-suppressor microRNA replacement therapy in ovarian cancer. *Biochemical and Biophysical Research Communications*, *527*(1), 153–161. https://doi.org/10.1016/j.bbrc.2020.04.076

Kuroki, L., & Guntupalli, S. R. (2020). Treatment of epithelial ovarian cancer. *BMJ*, m3773. https://doi.org/10.1136/bmj.m3773

Lau, T. S., Chan, L. K. Y., Man, G. C. W., Wong, C. H., Lee, J. H. S., Yim, S. F., Cheung, T. H., McNeish, I. A., & Kwong, J. (2020). Paclitaxel Induces Immunogenic Cell Death in Ovarian Cancer via TLR4/IKK2/SNARE-Dependent Exocytosis. *Cancer Immunology Research*, *8*(8), 1099–1111. https://doi.org/10.1158/2326-6066.CIR-19-0616

Le Saux, O., Ray-Coquard, I., & Labidi-Galy, S. I. (2021). Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer. *Seminars in Cancer Biology*, *77*, 127–143. https://doi.org/10.1016/j.semcancer.2020.08.017

Lecker, L. S. M., Berlato, C., Maniati, E., Delaine-Smith, R., Pearce, O. M. T., Heath, O., Nichols, S. J., Trevisan, C., Novak, M., McDermott, J., Brenton, J. D., Cutillas, P. R., Rajeeve, V., Hennino, A., Drapkin, R., Loessner, D., & Balkwill, F. R. (2021). TGFBI Production by Macrophages Contributes to an Immunosuppressive Microenvironment in Ovarian Cancer. *Cancer Research*, *81*(22), 5706–5719. https://doi.org/10.1158/0008-5472.CAN-21-0536

Li, X., Pan, Y., Chen, H., Duan, Y., Zhou, S., Wu, W., Wang, S., & Liu, B. (2020). Specific Near-Infrared Probe for Ultrafast Imaging of Lysosomal β-Galactosidase in Ovarian Cancer Cells. *Analytical Chemistry*, *92*(8), 5772–5779. https://doi.org/10.1021/acs.analchem.9b05121

Liu, W., Wang, W., Wang, X., Xu, C., Zhang, N., & Di, W. (2020). Cisplatin-stimulated macrophages promote ovarian cancer migration via the CCL20-CCR6 axis. *Cancer Letters*, *472*, 59–69. https://doi.org/10.1016/j.canlet.2019.12.024

Marchetti, C., De Felice, F., Romito, A., Iacobelli, V., Sassu, C. M., Corrado, G., Ricci, C., Scambia, G., & Fagotti, A. (2021). Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments. *Seminars in Cancer Biology*, *77*, 144–166. https://doi.org/10.1016/j.semcancer.2021.08.011

McMullen, M., Karakasis, K., Madariaga, A., & Oza, A. M. (2020). Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer. *Cancers*, *12*(6), 1607. https://doi.org/10.3390/cancers12061607

Miyamoto, T., Murakami, R., Hamanishi, J., Tanigaki, K., Hosoe, Y., Mise, N., Takamatsu, S., Mise, Y., Ukita, M., Taki, M., Yamanoi, K., Horikawa, N., Abiko, K., Yamaguchi, K., Baba, T., Matsumura, N., & Mandai, M. (2022). B7-H3 Suppresses Antitumor Immunity via the CCL2–CCR2–M2 Macrophage Axis and Contributes to Ovarian Cancer Progression. *Cancer Immunology Research*, *10*(1), 56–69. https://doi.org/10.1158/2326-6066.CIR-21-0407

Mukherjee, A., Chiang, C.-Y., Daifotis, H. A., Nieman, K. M., Fahrmann, J. F., Lastra, R. R., Romero, I. L., Fiehn, O., & Lengyel, E. (2020). Adipocyte-Induced FABP4 Expression in Ovarian Cancer Cells Promotes Metastasis and Mediates Carboplatin Resistance. *Cancer Research*, *80*(8), 1748–1761. https://doi.org/10.1158/0008-5472.CAN-19-1999

Nacarelli, T., Fukumoto, T., Zundell, J. A., Fatkhutdinov, N., Jean, S., Cadungog, M. G., Borowsky, M. E., & Zhang, R. (2020). NAMPT Inhibition Suppresses Cancer Stem-like Cells Associated with Therapy-Induced Senescence in Ovarian Cancer. *Cancer Research*, *80*(4), 890–900. https://doi.org/10.1158/0008-5472.CAN-19-2830

Nash, Z., & Menon, U. (2020). Ovarian cancer screening: Current status and future directions. *Best Practice & Research Clinical Obstetrics & Gynaecology*, *65*, 32–45. https://doi.org/10.1016/j.bpobgyn.2020.02.010

Rickard, B. P., Conrad, C., Sorrin, A. J., Ruhi, M. K., Reader, J. C., Huang, S. A., Franco, W., Scarcelli, G., Polacheck, W. J., Roque, D. M., Del Carmen, M. G., Huang, H.-C., Demirci, U., & Rizvi, I. (2021). Malignant Ascites in Ovarian Cancer: Cellular, Acellular, and Biophysical Determinants of Molecular Characteristics and Therapy Response. *Cancers*, *13*(17), 4318. https://doi.org/10.3390/cancers13174318

Samadi Pakchin, P., Fathi, M., Ghanbari, H., Saber, R., & Omidi, Y. (2020). A novel electrochemical immunosensor for ultrasensitive detection of CA125 in ovarian cancer. *Biosensors and Bioelectronics*, *153*, 112029. https://doi.org/10.1016/j.bios.2020.112029

Sun, H., Wang, H., Wang, X., Aoki, Y., Wang, X., Yang, Y., Cheng, X., Wang, Z., & Wang, X. (2020). Aurora-A/SOX8/FOXK1 signaling axis promotes chemoresistance via suppression of cell senescence and induction of glucose metabolism in ovarian cancer organoids and cells. *Theranostics*, *10*(15), 6928–6945. https://doi.org/10.7150/thno.43811

Tossetta, G., Fantone, S., Montanari, E., Marzioni, D., & Goteri, G. (2022). Role of NRF2 in Ovarian Cancer. *Antioxidants*, *11*(4), 663. https://doi.org/10.3390/antiox11040663

Wan, C., Keany, M. P., Dong, H., Al-Alem, L. F., Pandya, U. M., Lazo, S., Boehnke, K., Lynch, K. N., Xu, R., Zarrella, D. T., Gu, S., Cejas, P., Lim, K., Long, H. W., Elias, K. M., Horowitz, N. S., Feltmate, C. M., Muto, M. G., Worley, M. J., … Hill, S. J. (2021). Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer. *Cancer Research*, *81*(1), 158–173. https://doi.org/10.1158/0008-5472.CAN-20-1674

Wang, J., Ding, W., Xu, Y., Tao, E., Mo, M., Xu, W., Cai, X., Chen, X., Yuan, J., & Wu, X. (2020). Long non-coding RNA RHPN1-AS1 promotes tumorigenesis and metastasis of ovarian cancer by acting as a ceRNA against miR-596 and upregulating LETM1. *Aging*, *12*(5), 4558–4572. https://doi.org/10.18632/aging.102911

Wang, Y., Zhao, G., Condello, S., Huang, H., Cardenas, H., Tanner, E. J., Wei, J., Ji, Y., Li, J., Tan, Y., Davuluri, R. V., Peter, M. E., Cheng, J.-X., & Matei, D. (2021). Frizzled-7 Identifies Platinum-Tolerant Ovarian Cancer Cells Susceptible to Ferroptosis. *Cancer Research*, *81*(2), 384–399. https://doi.org/10.1158/0008-5472.CAN-20-1488

Xiong, J., Wu, M., Chen, J., Liu, Y., Chen, Y., Fan, G., Liu, Y., Cheng, J., Wang, Z., Wang, S., Liu, Y., & Zhang, W. (2021). Cancer-Erythrocyte Hybrid Membrane-Camouflaged Magnetic Nanoparticles with Enhanced Photothermal-Immunotherapy for Ovarian Cancer. *ACS Nano*, *15*(12), 19756–19770. https://doi.org/10.1021/acsnano.1c07180

Xuan, Y., Wang, H., Yung, M. M., Chen, F., Chan, W.-S., Chan, Y.-S., Tsui, S. K., Ngan, H. Y., Chan, K. K., & Chan, D. W. (2022). SCD1/FADS2 fatty acid desaturases equipoise lipid metabolic activity and redox-driven ferroptosis in ascites-derived ovarian cancer cells. *Theranostics*, *12*(7), 3534–3552. https://doi.org/10.7150/thno.70194

Yang, Z., Xu, H., & Zhao, X. (2020). Designer Self-Assembling Peptide Hydrogels to Engineer 3D Cell Microenvironments for Cell Constructs Formation and Precise Oncology Remodeling in Ovarian Cancer. *Advanced Science*, *7*(9), 1903718. https://doi.org/10.1002/advs.201903718

Zhang, K., Erkan, E. P., Jamalzadeh, S., Dai, J., Andersson, N., Kaipio, K., Lamminen, T., Mansuri, N., Huhtinen, K., Carpén, O., Hietanen, S., Oikkonen, J., Hynninen, J., Virtanen, A., Häkkinen, A., Hautaniemi, S., & Vähärautio, A. (2022). Longitudinal

single-cell RNA-seq analysis reveals stress-promoted chemoresistance in metastatic ovarian cancer. *Science Advances*, *8*(8), eabm1831. https://doi.org/10.1126/sciadv.abm1831

Zhang, M., Cheng, S., Jin, Y., Zhao, Y., & Wang, Y. (2021). Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer. *Biochimica et Biophysica Acta (BBA) - Reviews on Cancer*, *1875*(2), 188503. https://doi.org/10.1016/j.bbcan.2021.188503

Zhang, Q.-F., Li, J., Jiang, K., Wang, R., Ge, J., Yang, H., Liu, S.-J., Jia, L.-T., Wang, L., & Chen, B.-L. (2020). CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner. *Theranostics*, *10*(23), 10619–10633. https://doi.org/10.7150/thno.44871

Zheng, F., Zhang, Y., Chen, S., Weng, X., Rao, Y., & Fang, H. (2020). Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer. *Biomedicine & Pharmacotherapy*, *123*, 109661. https://doi.org/10.1016/j.biopha.2019.109661

Zhou, J., Jiang, Y., Chen, H., Wu, Y., & Zhang, L. (2020). RETRACTED: Tanshinone I attenuates the malignant biological properties of ovarian cancer by inducing apoptosis and autophagy via the inactivation of PI3K/AKT/mTOR pathway. *Cell Proliferation*, *53*(2), e12739. https://doi.org/10.1111/cpr.12739